Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.

[1]  M. Koch,et al.  Survival and predictors of death in dialysed diabetic patients , 1993, Diabetologia.

[2]  Martin Schumacher,et al.  Sample sizes for clinical trials with time-to-event endpoints and competing risks. , 2005, Contemporary clinical trials.

[3]  Philip J. Barter,et al.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[4]  J. Bragg-Gresham,et al.  HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[5]  John Simes,et al.  Effect of Pravastatin on Cardiovascular Events in People With Chronic Kidney Disease , 2004, Circulation.

[6]  W. März,et al.  Randomized Controlled Trial on the Efficacy and Safety of Atorvastatin in Patients with Type 2 Diabetes on Hemodialysis (4D Study): Demographic and Baseline Characteristics , 2004, Kidney and Blood Pressure Research.

[7]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[8]  J. Armitage,et al.  Cardiovascular outcomes among participants with diabetes in the recent large statin trials , 2004, Current opinion in lipidology.

[9]  Neil J Stone,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.

[10]  B. Cheung,et al.  Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. , 2004, British journal of clinical pharmacology.

[11]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[12]  S. Prichard.  Impact of dyslipidemia in end-stage renal disease. , 2003, Journal of the American Society of Nephrology : JASN.

[13]  T. Meyer,et al.  Urämische Patienten - späte Überweisung, früher Tod , 2003 .

[14]  N. Lameire,et al.  Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[15]  W. Hörl,et al.  [Uremic patients--late referral, early death]. , 2003, Deutsche medizinische Wochenschrift.

[16]  Peter Stenvinkel,et al.  The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. , 2002, Kidney international.

[17]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[18]  K. Iseki,et al.  Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. , 2002, Kidney international.

[19]  Ethan M Balk,et al.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[20]  K Doqi,et al.  clinical practice guidelines for chronic kidney disease : evaluation, classification, and stratification , 2002 .

[21]  B. Kestenbaum,et al.  HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. , 2002, Kidney international.

[22]  Colin Baigent,et al.  Premature cardiovascular disease in chronic renal failure , 2000, The Lancet.

[23]  W. März,et al.  Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis , 1999 .

[24]  R. Foley,et al.  Clinical epidemiology of cardiovascular disease in chronic renal disease. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[25]  K. Shimokata,et al.  Immunohistochemical detection of imidazolone and N(epsilon)-(carboxymethyl)lysine in aortas of hemodialysis patients. , 1998, Cellular and molecular biology.

[26]  E. Ritz,et al.  Myocyte/capillary mismatch in the heart of uremic patients. , 1998, Journal of the American Society of Nephrology : JASN.

[27]  F. Kronenberg,et al.  Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients. , 1997, Journal of the American Society of Nephrology : JASN.

[28]  M Nauck,et al.  Quantitative determination of high-, low-, and very-low-density lipoproteins and lipoprotein(a) by agarose gel electrophoresis and enzymatic cholesterol staining. , 1995, Clinical chemistry.

[29]  Scandinavian Simvastatin Survival Study Group.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[30]  E. Ritz,et al.  Serum lipids predict cardiac death in diabetic patients on maintenance hemodialysis. Results of a prospective study. The German Study Group Diabetes and Uremia. , 1993, Nephron.

[31]  P. O'Brien,et al.  A multiple testing procedure for clinical trials. , 1979, Biometrics.